Paula Soteropoulos joined 5AM Ventures in 2020 and serves as a Strategic Advisor. With more than 30 years in the biopharma industry in areas of drug development, manufacturing, business development, global commercialization with P&L accountability, and company building, Ms. Soteropoulos' leadership throughout her career spans a broad range of therapeutic areas, including rare disease, cardiovascular and metabolism, infectious disease, renal, and transplant and oncology.

She is the Chairman of Ensoma, having worked with the founding team to launch the company, establish strategic priorities and build-out the leadership team.

She also serves on the board of directors of Dianthus, Rallybio and uniQure, and most recently served as the CEO and a member of the board of directors of rare disease therapeutic developer, Akcea Therapeutics. Ms. Soteropoulos serves on the Advisory Boards for Chiesi Rare Disease, Kyowa Kirin North America and the Tufts University Chemical and Biological Engineering Department.

She is in active mentor and coach for Women in Bio Boardroom-ready program and the Termeer Foundation for next-generation entrepreneurs. Ms. Soteropoulos is based in Boston, MA.